{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:50:39Z","timestamp":1791805839469,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eprac.2026.09.005","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:29:32Z","timestamp":1789831772000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes in Body Composition Assessed by Bioelectrical Impedance Analysis in Patients Treated With Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Experience"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1753-0350","authenticated-orcid":false,"given":"Jose","family":"Atencia Go\u00f1i","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3324-5798","authenticated-orcid":false,"given":"Mercedes","family":"S\u00e1nchez Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6831-6226","authenticated-orcid":false,"given":"Gilberto","family":"P\u00e9rez L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Monereo Meg\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4083-6200","authenticated-orcid":false,"given":"Olga","family":"Gonz\u00e1lez Albarr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2026.09.005_bib1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11695-013-1079-8","article-title":"Interdisciplinary European guidelines on metabolic and bariatric surgery","volume":"24","author":"Fried","year":"2014","journal-title":"Obes Surg"},{"key":"10.1016\/j.eprac.2026.09.005_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.706978","article-title":"Obesity: epidemiology, pathophysiology, and therapeutics","volume":"12","author":"Lin","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eprac.2026.09.005_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000544880","article-title":"The Spanish GIRO guideline: a paradigm shift in the management of obesity in adults","volume":"18","author":"Lecube","year":"2025","journal-title":"Obes Facts"},{"key":"10.1016\/j.eprac.2026.09.005_bib4","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","article-title":"A new framework for the diagnosis, staging and management of obesity in adults","volume":"30","author":"Busetto","year":"2024","journal-title":"Nat Med"},{"issue":"31","key":"10.1016\/j.eprac.2026.09.005_bib5","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"CMAJ"},{"issue":"11","key":"10.1016\/j.eprac.2026.09.005_bib6","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2026.09.005_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000497124","article-title":"The ABCD of obesity: an EASO position statement on a diagnostic term with clinical and scientific implications","volume":"12","author":"Fr\u00fchbeck","year":"2019","journal-title":"Obes Facts"},{"key":"10.1016\/j.eprac.2026.09.005_bib8","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnaa004","article-title":"Metabolically healthy obesity","volume":"41","author":"Bl\u00fcher","year":"2020","journal-title":"Endocr Rev"},{"key":"10.1016\/j.eprac.2026.09.005_bib9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S2213-8587(19)30084-1","article-title":"Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement","volume":"7","author":"Neeland","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2026.09.005_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11154-022-09780-3","article-title":"Bioimpedance basics and phase angle fundamentals","volume":"24","author":"Ward","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.eprac.2026.09.005_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.eprac.2026.09.005_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2026.09.005_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.09.005_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1172\/JCI30227","article-title":"Gastrointestinal regulation of food intake","volume":"117","author":"Cummings","year":"2007","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.eprac.2026.09.005_bib15","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.eprac.2026.09.005_bib16","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.09.005_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.eprac.2026.09.005_bib18","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.09.005_bib19","series-title":"The nutrition source","article-title":"Chan school of public health. Healthy eating plate","author":"Harvard","year":"2011"},{"issue":"4","key":"10.1016\/j.eprac.2026.09.005_bib20","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/oby.23120","article-title":"Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic","volume":"29","author":"Acosta","year":"2021","journal-title":"Obesity"},{"issue":"3","key":"10.1016\/j.eprac.2026.09.005_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1753-0407.70063","article-title":"Sex differences in the efficacy of glucagon-like Peptide-1 receptor agonists for weight reduction: a systematic review and meta-analysis","volume":"17","author":"Yang","year":"2025","journal-title":"J Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2026.09.005_bib22","doi-asserted-by":"crossref","DOI":"10.1080\/13685538.2025.2601423","article-title":"The male hormone reset: how GLP-1RAs, lifestyle and testosterone transform obesity-linked problems","volume":"28","author":"Antoni\u010d","year":"2025","journal-title":"Aging Male"},{"key":"10.1016\/j.eprac.2026.09.005_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.paid.2025.113423","article-title":"Negative affectivity and social inhibition as independent predictors of eating behaviors and adiposity: a study on Type D personality traits","volume":"247","author":"Atan","year":"2025","journal-title":"Personal Individual Differences"},{"key":"10.1016\/j.eprac.2026.09.005_bib24","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/s41366-026-02088-1","article-title":"GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"50","author":"Sawicka-Gutaj","year":"2026","journal-title":"Int J Obes (Lond)"},{"issue":"9","key":"10.1016\/j.eprac.2026.09.005_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/diseases12090204","article-title":"The effect of tirzepatide on body composition in people with overweight and obesity: a systematic review of randomized, controlled studies","volume":"12","author":"Rochira","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.eprac.2026.09.005_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.clnesp.2026.103305","article-title":"Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: protein strategies, micronutrient monitoring, and lean mass preservation","volume":"73","author":"Arslan","year":"2026","journal-title":"Clin Nutr ESPEN"},{"issue":"10","key":"10.1016\/j.eprac.2026.09.005_bib27","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dci23-0100","article-title":"Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?","volume":"47","author":"Locatelli","year":"2024","journal-title":"Diabetes Care"},{"issue":"February","key":"10.1016\/j.eprac.2026.09.005_bib28","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2147\/DMSO.S443631","article-title":"Assessment of changes in body composition after 3 months of dulaglutide treatment","volume":"17","author":"Chen","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.eprac.2026.09.005_bib29","doi-asserted-by":"crossref","first-page":"1386542","DOI":"10.3389\/fendo.2024.1386542","article-title":"Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus","volume":"15","author":"Rodr\u00edguez Jim\u00e9nez","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.eprac.2026.09.005_bib30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/dom.70141","article-title":"Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study","volume":"28","author":"Alissou","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.eprac.2026.09.005_bib31","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.eprac.2026.09.005_bib32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.amjopharm.2011.09.007","article-title":"Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes \u226565 and <65 years of age: a pooled analysis from phase III studies","volume":"9","author":"Bode","year":"2011","journal-title":"Am J Geriatr Pharmacother"},{"issue":"10516","key":"10.1016\/j.eprac.2026.09.005_bib33","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","article-title":"Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial","volume":"406","author":"Deanfield","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2026.09.005_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102624","article-title":"Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial","volume":"72","author":"Hansen","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.eprac.2026.09.005_bib35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/oby.24172","article-title":"GLP1Ra-based therapies and DXA-acquired musculoskeletal health outcomes: a focused meta-analysis of placebo-controlled trials","volume":"33","author":"Beavers","year":"2025","journal-title":"Obesity"},{"key":"10.1016\/j.eprac.2026.09.005_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107927","article-title":"Glucagon-like peptide-1 receptor agonists and muscle mass effects","volume":"220","author":"Ceasovschih","year":"2025","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.eprac.2026.09.005_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41413-025-00483-4","article-title":"Weight loss induced bone loss: mechanism of action and clinical implications","volume":"13","author":"Liu","year":"2025","journal-title":"Bone Res"},{"issue":"3","key":"10.1016\/j.eprac.2026.09.005_bib38","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/osp4.116","article-title":"Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence","volume":"3","author":"Carls","year":"2017","journal-title":"Obes Sci Pract"},{"issue":"6","key":"10.1016\/j.eprac.2026.09.005_bib39","first-page":"669","article-title":"The effect of early response to GLP-1 RA therapy on long-term adherence and persistence among type 2 diabetes patients in the United States","volume":"25","author":"Durden","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"10.1016\/j.eprac.2026.09.005_bib40","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/s41591-025-03645-3","article-title":"Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery","volume":"31","author":"German","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.eprac.2026.09.005_bib41","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41430-018-0335-3","article-title":"Bioelectrical impedance analysis for body composition assessment: reflections on accuracy, clinical utility, and standardisation","volume":"73","author":"Ward","year":"2019","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.eprac.2026.09.005_bib42","doi-asserted-by":"crossref","DOI":"10.1186\/s42269-025-01374-8","article-title":"The weight-loss paradox in older adults: balancing fat loss with muscle preservation","volume":"49","author":"Arslan","year":"2025","journal-title":"Bull Natl Res Cent"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2601147X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2601147X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:36:39Z","timestamp":1791804999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2601147X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"alternative-id":["S1530891X2601147X"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.09.005","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in Body Composition Assessed by Bioelectrical Impedance Analysis in Patients Treated With Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Experience","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}